LemnaGene SA

Biomanufacturing company opens new facility, produces first transgenic Spirodela

Published in Healthcare Finance, Tax and Law Weekly, October 27th, 2004

LemnaGene SA opened its new laboratory and biomanufacturing facility in the incubation space for new projects, located at the Ecole normale superieure de Lyon (France) (ENS Lyon), allowing the company to provide a full range of biomanufacturing services to the pharmaceutical, vaccine, veterinarian, diagnostic, nutraceutical, and industrial protein markets.

LemnaGene SA also announced the production of its first transgenic Spirodela containing genes of interest to industrial partners.

Georges Freyssinet, the chief executive officer of LemnaGene SA, commented, "This new facility is a big plus for us. We can now produce efficiently transgenic Spirodela...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2004-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry